EHMT1 and chronic myelogenous leukemia, BCR-ABL1 positive: In this study, we demonstrate that inhibition of EHMT1 and EHMT2 with specific chemical inhibitors in several CML cell lines sensitizes cells to interferon and imatinib treatments.